MergerAug 7, 2026, 05:07 PM
Gyre Therapeutics Completes Merger with Cullgen; Reports Q2 Loss
AI Summary
Gyre Therapeutics, Inc. completed its merger with Cullgen Inc. on May 4, 2026, a transaction accounted for as a common control merger. For the six months ended June 30, 2026, the company reported a net loss of $32.8 million, a significant decline from a net income of $2.7 million in the prior year. Revenues decreased to $53.5 million from $60.3 million, while total operating expenses rose to $86.9 million. The company ended the period with $43.3 million in cash and cash equivalents.
Key Highlights
- Merger with Cullgen Inc. completed on May 4, 2026, accounted for as a common control transaction.
- Net loss of $32.8 million for the six months ended June 30, 2026, compared to $2.7 million net income in 2025.
- Revenues decreased to $53.5 million for the six months ended June 30, 2026, from $60.3 million in 2025.
- Total operating expenses increased to $86.9 million for the six months ended June 30, 2026, from $60.0 million in 2025.
- Basic net loss per share was $0.26 for the six months ended June 30, 2026, compared to $0.00 in 2025.
- Cash and cash equivalents stood at $43.3 million as of June 30, 2026.
- Total equity significantly increased to $142.5 million as of June 30, 2026, from $59.5 million at December 31, 2025.
Price Impact
More from GYRE